TY - CHAP
T1 - Fragile X syndrome and targeted treatment trials
AU - Hagerman, Randi J
AU - Lauterborn, Julie
AU - Au, Jacky
AU - Berry-Kravis, Elizabeth
PY - 2012
Y1 - 2012
N2 - Work in recent years has revealed an abundance of possible new treatment targets for fragile X syndrome (FXS). The use of animal models, including the fragile X knockout mouse which manifests a phenotype very similar to FXS in humans, has resulted in great strides in this direction of research. The lack of Fragile X Mental Retardation Protein (FMRP) in FXS causes dysregulation and usually overexpression of a number of its target genes, which can cause imbalances of neurotransmission and deficits in synaptic plasticity. The use of metabotropic glutamate receptor (mGluR) blockers and gamma amino-butyric acid (GABA) agonists have been shown to be efficacious in reversing cellular and behavioral phenotypes, and restoring proper brain connectivity in the mouse and fly models. Proposed new pharmacological treatments and educational interventions are discussed in this chapter. In combination, these various targeted treatments show promising preliminary results in mitigating or even reversing the neurobiological abnormalities caused by loss of FMRP, with possible translational applications to other neurodevelopmental disorders including autism.
AB - Work in recent years has revealed an abundance of possible new treatment targets for fragile X syndrome (FXS). The use of animal models, including the fragile X knockout mouse which manifests a phenotype very similar to FXS in humans, has resulted in great strides in this direction of research. The lack of Fragile X Mental Retardation Protein (FMRP) in FXS causes dysregulation and usually overexpression of a number of its target genes, which can cause imbalances of neurotransmission and deficits in synaptic plasticity. The use of metabotropic glutamate receptor (mGluR) blockers and gamma amino-butyric acid (GABA) agonists have been shown to be efficacious in reversing cellular and behavioral phenotypes, and restoring proper brain connectivity in the mouse and fly models. Proposed new pharmacological treatments and educational interventions are discussed in this chapter. In combination, these various targeted treatments show promising preliminary results in mitigating or even reversing the neurobiological abnormalities caused by loss of FMRP, with possible translational applications to other neurodevelopmental disorders including autism.
UR - http://www.scopus.com/inward/record.url?scp=80555146668&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80555146668&partnerID=8YFLogxK
U2 - 10.1007/978-3-642-21649-7_17
DO - 10.1007/978-3-642-21649-7_17
M3 - Chapter
C2 - 22009360
AN - SCOPUS:80555146668
SN - 9783642216480
VL - 54
T3 - Results and Problems in Cell Differentiation
SP - 297
EP - 335
BT - Results and Problems in Cell Differentiation
ER -